Evidence map›Paper›PMID 38371226›Full record

ArticleNeuro-oncology advances

The potential of liquid biopsy for detection of the KIAA1549-BRAF fusion in circulating tumor DNA from children with pilocytic astrocytoma.

Olha Krynina, Teresita Díaz de Ståhl, Cecilia Jylhä, Cecilia Arthur, Geraldine Giraud, Per Nyman, Anders Fritzberg, Johanna Sandgren, Emma Tham, Ulrika Sandvik

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Olha KryninaDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0009-0006-6911-557X
Teresita Díaz de StåhlDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Cecilia JylhäDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Cecilia ArthurDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Geraldine GiraudDepartment of Immunology, Genetic and Pathology, Neuro-oncology, and Neurodegeneration Program Rudbeck Laboratory, Uppsala, Sweden.
Per NymanDepartment of Health, Crown Princess Victoria Children´s Hospital, Linköping University Hospital, Linköping, Sweden.
Anders FritzbergDaycare Unit of Oncology and Hematology, Clinic of Pediatrics Falun Hospital, Dalarna Region, Sweden.
Johanna SandgrenDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Emma ThamDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0001-6079-164X
Ulrika SandvikDepartment of Clinical Neuroscience, Division of Neurosurgery, Karolinska Institutet, Stockholm, Sweden.
Karolinska University Hospital · SEKarolinska Institutet · SEFalun Hospital · SELinköping University · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Low-grade gliomas (LGGs) represent children's most prevalent central nervous system tumor, necessitating molecular profiling to diagnose and determine the most suitable treatment. Developing highly sensitive screening techniques for liquid biopsy samples is particularly beneficial, as it enables the early detection and molecular characterization of tumors with minimally invasive samples. Methods: We examined CSF and plasma samples from patients with pilocytic astrocytoma (PA) using custom multiplexed droplet digital polymerase chain reaction (ddPCR) assays based on whole genome sequencing data. These assays included a screening test to analyze Results: Our findings revealed that 5 out of 13 individual cerebrospinal fluid (CSF) samples tested positive for circulating tumor DNA (ctDNA). Among these cases, 3 exhibited the Conclusions: While CNV analysis of CSF samples from LGGs still has some limitations, it has the potential to serve as a valuable complementary tool. Furthermore, it can also be multiplexed with other aberrations, for example, to the

Indexed as

cerebrospinal fluidcfDNAddPCRKIAA1549::BRAFpilocytic astrocytoma

Identifiers

PMID38371226
PMCPMC10874216
OpenAlexW4391212323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.